Clinical Trial Update: Intravitreal Infliximab for Proliferative Vitreoretinopathy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating intravitreal infliximab for proliferative vitreoretinopathy has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Vitreoretinopathy
• Retinal Detachment
• Rhegmatogenous Retinal Detachment

Drugs mentioned

• Infliximab (infliximab)

Snippet

Sponsor: Cairo University | Conditions: Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy | Phase 2 | Status: COMPLETED